Application for MS Treatment Accepted by FDA

The US Food and Drug Administration will be testing a new drug intended for the treatment of multiple sclerosis relapses. Merck Sorono filed a New Drug Application for its Cladribine Tablets, which was immediately taken up by the FDA and granted Priority Review status. That means a lot to MS patients who will want to look for the medicine in online pharmacies, assuming it’s offered there.

This development is important because it actually shortens the FDA review period from the usual ten months to just six months. This also signifies that the drug actually has a lot of promise in the treatment of specific conditions.

Multiple sclerosis is a disease that affects the brain and spine, causing affected people to experience symptoms such as muscle weakness, numbness, memory problems, and others. The condition affects 350,000 adults in the United States, and most victims are adults 20 to 50 years old. Medical experts still don’t know for sure what causes MS, but medications such as Cladibrine and others relieve some of the symptoms. Online pharmacies will be waiting for the results of FDA testing for this new drug.